anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The study will include adults HFrEF patients, that despite guidelines directed medical therapy still retain a congestive heart failure (HF) picture. During the study, patients should remain on their prescribed heart failure medications and the same dosing schedule for the duration of the study unless investigators determine medically necessary to change. Patients will be assigned randomly to receive either PolyCore PUF (over the top of their prescribed heart failure medications), for 6 months, or to the control arm receiving stable medical therapy according to international guidelines and comprehensive of loop diuretic (furosemide) dose till to 2.5mg/kg/day, without PUF therapy. The PUF ultrafiltration will be performed with a single nightly exchange, with 2 liters PolyCore solution, lasting 12-14 hours, for 6 months. An independent data safety monitoring board (DSMB) will be convened for this study and will review the results of the trial at regular intervals to protect patients participating in the study. An adaptive interim analysis will be performed when in each group 20 patients have completed 6 months in the study, for analysis of the primary outcome. The purpose of the adaptive interim analysis is to calculate the final study sample size.The DSMB will closely examine the interim primary efficacy results, respecting the confidentiality and integrity of data, to investigate the final sample sizes necessary to complete the study.
A method for preparing virus-inactivated antiproteinase agent of broad spectrum comprises ethanol precipitation of plasma proteins according to Kohn technique from II+III fraction and separation of beta-lipoproteids followed by their purification by filtration and sterilizing filtration. II+III fraction is dissolved in phosphate buffer. Non-stable proteins are precipitated with 3 % solution of polyethylene glycol the presence of sorbitol as stabilizer at the temperature of 20-. Then sorption of α-macroglobulin follows. The solvent and detergent are removed by ion-exchange chromatography on the column packed with the sorbent containing DEAE group on the porous polymeric base followed by the desorption of antiproteinase agent with sodium acetate buffer at pH 6.0 with linear rate of 2-3 cm/min. The ultrafiltration is finally used for concentration with cut-off value of 300 kD.
The phrenic nerve innervates the respiratory diaphragm, the primary muscle active during ventilation. The canonical path of the phrenic nerve originates from the cervical spine at C3-C5 spinal nerves and travels inferiorly through the neck and thoracic cavity to reach the diaphragm. During a cadaver dissection, a variation of the phrenic nerve was discovered in a 93-year-old male specimen. A traditional origin of the phrenic nerve was noted; however, the nerve branched into medial and lateral components at the level of the superior trunk of the brachial plexus. The branches reconnected at the apex of the aortic arch and continued inferiorly to innervate the ipsilateral diaphragm. This case study describes a rare type of branching of the phrenic nerve and explores its potential impact on clinical procedures.
A control group of dental patients matched for age (±3 years), gender, and risk factors for CAD (hypertension, obesity, diabetes, smoking, hypercholesterolaemia and family history) but with no history of myocardial infarction will be selected at Aberdeen Dental School or from the SHARE register or via the NHS Research Scotland Primary Care Network on an invitation basis. Thr recruitment of this arm of the study is ongoing.
The efficacy of REBLOZYL was evaluated in the COMMANDS trial (NCT03682536), a multi‑center, open‑label, randomized active‑controlled trial comparing REBLOZYL versus epoetin alfa in patients with anemia due to IPSS‑R very low, low, or intermediate‑risk myelodysplastic syndromes or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN RS‑T) in ESA‑naïve patients (with endogenous sEPO levels of < 500 U/L) who require regular red blood cell transfusions. For eligibility, patients were required to have had 2 to 6 RBC units/8 weeks confirmed for a minimum of 8 weeks immediately preceding randomization.

The COMMANDS trial included 356 patients randomized 1:1 to REBLOZYL (N=178) or epoetin alfa (N=178). Randomization was stratified by RBC transfusion burden, RS status, and endogenous serum erythropoietin (sEPO) level at baseline. Treatment was started at 1 mg/kg subcutaneously every 3 weeks. Two dose level increases were allowed (to 1.33 mg/kg and to 1.75 mg/kg). Doses were held and subsequently reduced for adverse reactions, reduced if the hemoglobin increased by ≥ 2 g/dL from the prior cycle, and held if the predose hemoglobin was ≥ 12 g/dL.

All patients received best supportive care, which included RBC transfusions as needed. Patients were treated for 24 weeks and were assessed for efficacy at that time point. Treatment beyond 24 weeks was optional based upon response to treatment and absence of disease progression.

The median age of the 356 study participants was 74 years (range: 33, 93 years). The trial population was 56% male and 44% female; 79.5% were White, 0.6% Black or African American, 12.1% Asian, and race was not reported in 7.9% of patients. Ethnicities were reported as 85.4% for Not Hispanic or Latino patients, 6.5% for Hispanic or Latino patients, 7.6% for patients with no ethnicity reported, and 0.6% were unknown. IPSS‑R risk classification at baseline was 9.3% very low, 72.2% low, 17.4% intermediate, 0.3% high, and 0.8% missing. Table 14 summarizes the baseline disease‑related characteristics in the COMMANDS study.

The efficacy of REBLOZYL in the treatment of anemia in ESA‑naïve adult patients with MDS was established at the time of the interim efficacy analysis based upon the proportion of patients who experienced both red blood cell transfusion independence (RBC‑TI) [defined as the absence of any RBC transfusion during any consecutive 12‑week period] and an associated concurrent mean improvement in hemoglobin by at least 1.5 g/dL for any consecutive 12 week period during Weeks 1-24.

At the time of the interim efficacy analysis, 301 subjects were included in the efficacy analysis, of which 147 were in the luspatercept arm and 154 were in the epoetin alfa arm, which is about 85% of the total information. The key efficacy results are shown in Table 15.

No major outliers were observed in clinically relevant baseline demographic and disease characteristic subgroups.
OBJECTIVES: Endometrial cancer is a collection of heterogeneous histologies and molecular subtypes with different risk profiles. High-risk endometrial cancer surveillance regimens vary amongst providers. The National Comprehensive Cancer Network (NCCN) recommends symptom and exam-based surveillance for all endometrial cancers after remission, regardless of cancer stage and histology. Our objective was to identify the first method of detection of recurrence in high-risk endometrial cancers and examine disease recurrence and treatment patterns.
METHODS: A retrospective review of patients diagnosed with high-risk endometrial cancer between November 2013 and February 2020 was conducted at a large academic institution. High-risk endometrial cancers were classified by histology and pathologic stage and were categorized by primary method of detection.
RESULTS: Two hundred and twenty-nine patients were identified with high-risk endometrial cancer, 63 (28 %) of whom had a recurrence. Most recurrences were first detected with routine imaging in 31 patients (49.2 %) and symptom surveillance in 24 patients (38.15 %). Regardless of the detection method, most patients underwent systemic treatment. The average survival after recurrence was 2.0 years in the imaging cohort and 1.6 years in the non-imaging surveillance cohort.
CONCLUSIONS: The most common site of recurrence in our cohort of high-risk endometrial cancer was in the lung, and most recurrences were identified with asymptomatic imaging. Though there was no statistically significant difference between the survival of those who underwent imaging surveillance vs. standard of care, there was a trend toward survival that deems further exploration with a larger cohort.
BACKGROUND: Radical cystectomy (RC) is a major surgery associated with a high morbidity rate. Perioperative fluid management according to enhanced recovery after surgery (ERAS) protocols aims to maintain patients in an optimal euvolemic state while exposing them to acute kidney injury (AKI) in the event of hypovolemia. Postoperative AKI is associated with severe morbidity and mortality. Our main objective was to determine the association between perioperative variables, including some component of ERAS protocols, and occurrence of postoperative AKI within the first 30 days following RC in patients presenting bladder cancer. Our secondary objective was to evaluate the association between a postoperative AKI and the occurrence or worsening of a chronic kidney disease (CKD) within the 2 years following RC.
METHODS: We conducted a retrospective observational study in a referral cancer center in France on 122 patients who underwent an elective RC for bladder cancer from 01/02/2015 to 30/09/2019. The primary endpoint was occurrence of AKI between surgery and day 30. The secondary endpoint was survival without occurrence or worsening of a postoperative CKD. AKI and CKD were defined by KDIGO (Kidney Disease: Improving Global Outcomes) classification. Logistic regression analyse was used to determine independent factors associated with postoperative AKI. Fine and Gray model was used to determine independent factors associated with postoperative CKD.
RESULTS: The incidence of postoperative AKI was 58,2% (n = 71). Multivariate analysis showed 5 factors independently associated with postoperative AKI: intraoperative restrictive vascular filling < 5ml/kg/h (OR = 4.39, 95%CI (1.05-18.39), p = 0.043), postoperative sepsis (OR = 4.61, 95%CI (1.05-20.28), p = 0.043), female sex (OR = 0.11, 95%CI (0.02-0.73), p = 0.022), score SOFA (Sequential Organ Failure Assessment) at day 1 (OR = 2.19, 95%CI (1.15-4.19), p = 0.018) and delta serum creatinine D1 (OR = 1.06, 95%CI (1.02-1.11), p = 0.006). During the entire follow-up, occurrence or worsening of CKD was diagnosed in 36 (29.5%). A postoperative, AKI was strongly associated with occurrence or worsening of a CKD within the 2 years following RC even after adjustment for confounding factors (sHR = 2.247, 95%CI [1.051-4.806, p = 0.037]).
CONCLUSION: A restrictive intraoperative vascular filling < 5ml/kg/h was strongly and independently associated with the occurrence of postoperative AKI after RC in cancer bladder patients. In this context, postoperative AKI was strongly associated with the occurrence or worsening of CKD within the 2 years following RC. A personalized perioperative fluid management strategy needs to be evaluated in these high-risk patients.
The practice of Shinrin-Yoku, also known as Forest Bathing, is an outdoor therapeutic modality with growing evidence suggesting positive effects on the psychological well-being and general health of individuals. However, its benefits have been studied mainly in Asian countries, needing further research to assess whether its benefits are also generalizable to other European-Mediterranean regions. To explore this question, the investigators intend to evaluate patients aged 18 to 99 years with symptoms of anxiety and/or mild depression. A randomized controlled clinical trial will be carried out to evaluate the impact of the guided practice of forest bathing. The participants will be randomly distributed in two arms, with a crossover design: arm A intervention + control; arm B control + intervention. Participation in this study consists of the execution of two sessions of guided forest bathing practice, and the completion of online evaluation forms before and after each session of guided forest bathing practice, for 24 hours afterwards, as well as before and after the program as a whole. The study includes clinical assessments, emotional well-being, social support and other complementary indicators. For hypothesis testing, a linear model of univariate analysis of variance intrasubject design will be applied to the dependent variables, with three phase conditions (pre, post and follow-up) and two treatment conditions (intervention vs. control).
The present invention relates to novel, bifunctional inhibitors of both platelet activation and thrombin. These bifunctional inhibitors are characterized by two domains - a glycoprotein IIb/IIIa inhibitory domain and a thrombin inhibitory domain. The invention also relates to DNA sequences which encode the bifunctional inhibitors of this invention, recombinant DNA molecules which contain these DNA sequences and host transformed with these DNA  molecules. The invention further relates to the recombinant expression of the bifunctional inhibitors of this invention by transformed hosts as well as to methods for purifying such recombinant bifunctional inhibitors. This invention also provides compositions and methods employing the novel bifunctional inhibitors alone or together with a fibrinolytic agent. Such compositions may be useful in patients for treating thrombotic disease, increasing reocclusion time, decreasing reperfusion time, simultaneously inhibiting thrombin- and platelet-mediated functions and inhibiting malignant cell growth.
1. In a method of radiation treatment of a human or non-human mammalian subject which comprises administering to said subject a therapeutically, prophylactically or pain-palliating amount of a bone-targeting complex of a radionuclide, the improvement comprising using as said radionuclide a radionuclide selected from the group consisting of alpha-particle emitting thorium radionuclides. 2. A method as claimed in claim 1 wherein said complex is administered parenterally by injection or infusion. 3. A method as claimed in either of claims 1 and 2 wherein said radionuclide is or thorium-227. 4. A method as claimed in any one of claims 1 to 3 wherein said complex is a complex of said radionuclide and a phosphonate complexing agent. 5. A method as claimed in any one of claims 1 to 3 wherein said complex is a complex of said radionuclide and a polyphosphonate complexing agent. 6. A method as claimed in any one of claims 1 to 5 being a method of therapeutic treatment and/or pain palliation of diseases affecting bones and/or soft tissue. 7. The use of an alpha particle emitting thorium radionuclide, or a bone-targeting complex thereof, for the manufacture of a medicament for use in a method of radiation treatment of a human or non-human mammalian subject which comprises administering to said subject a bone-targeting complex of said radionuclide. 8. Use as claimed in claim 7 wherein said radionuclide is thorium-227. 9. Use as claimed in either of claims 7 and 8 wherein said complex is a bisphosphonate or polyphosphonate complex. 10. Use as claimed in any one of claims 7 to 9 wherein said method is a method of therapeutic treatment and/or pain palliation of diseases affecting bones and/or soft tissue. 11. A radiopharmaceutical composition comprising a bone-targeting complex of a radionuclide selected from alpha-particle emitting thorium radionuclides, together with at least one physiologically acceptable carrier or excipient. 12. A composition as claimed in claim 11 wherein said radionuclide is thorium-227. 13. A composition as claimed in either of claims 11 and 12 wherein said complex is a bisphosphonate or polyphosphonate complex. 14. A bone-targeting complex of a radionuclide selected from alpha-particle emitting thorium radionuclides. 15. A complex as claimed in claim 14 of thorium-227 and bisphosphonate or polyphosphonate complex. 16. A kit for the treatment of bone surfaces or primary and/or metastatic cancers to the skeleton, comprising: an alpha-particle emitting thorium radioisotope, and a bone seeking chelator, for the preparation of physiologically compatible solutions of a thorium radioisotope chelate; a pharmaceutically acceptable carrier; and, optionally, administration equipment.
In San Francisco, HIV infection rates among men who have tested for HIV three or more times is almost triple the HIV infection rates of all other testers. Past research has shown that HIV uninfected gay and bisexual men who receive counseling are less likely to engage in high-risk sexual behavior. Counseling provided by trained mental health professionals within a clinical study setting helped individuals identify and re-evaluate their "self-justifications," which are their thoughts, attitudes, and beliefs when deciding to engage in unprotected sex. This study will focus on implementing a "real-world" counseling intervention designed specifically for men who are at the greatest risk of becoming infected with HIV: men who engage in high-risk sexual activity with other men and who repeatedly test for HIV. This specialized intervention will be administered by trained paraprofessional counselors during a pre-test counseling session prior to an HIV test. The purpose of this study is to evaluate the effectiveness of the specialized pre-test counseling intervention versus a standard pre-test counseling intervention in promoting safer sexual activity among HIV uninfected men. The men will have reported having unprotected sex with males of unknown HIV status or known HIV infection.

This 12-month study will enroll 300 men who will be recruited upon scheduling an anonymous HIV test at the participating clinic. Participants will be randomly assigned to receive either the enhanced pre-test counseling session or a standard pre-test counseling session prior to an HIV test. Outcome measurements will be assessed 6 and 12 months after the counseling session and will include self-reports of unprotected anal sex with non-primary partners and reported satisfaction levels with the pre-test counseling.
Participants receive decitabine IV over 1 hour on days 1-5 and enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
An antacid composition comprises a fatty agent selected from:-C8 and higher fatty amines and salts thereof, oils and fats, as herein defined, and at least one antacid selected from:-C8 and higher fatty amines and salts thereof, antacid oxides, carbonates, bicarbonates, subcarbonates and hydroxides, and dihydroxy aluminium amino acetate, and a flavouring agent when the fatty agent and antacid are the same substance.  The compositions may be in the form of powders, tablets, solutions, suspensions, or emulsions, and may contain conventional excipients.  The oils and fats are defined as esters of higher fatty acids and polyhydric alcohols.  Specified oils and fats are soya bean, safflower, palm, peanut, corn, cottonseed, coconut and sesame oils, cocoa butter, lard, butter fat, and mixtures of beef tallow with safflower oil, glyceryl monostearate with cottonseed oil, glyceryl monooleate with sesame oil, glyceryl oleo stearate with cottonseed oil, and propylene glycol monostearate with corn oil. Specified antacid oxides, carbonates, bicarbonates, subcarbonates, and hydroxides are MgO, MgCO3, CaCO3, Na2CO3, NaHCO3, (BIO)2CO3, Mg (OH)2, and Al(OH)3.  The compositions may also include other antacids e.g. Mg trisilicate.  The C8 and higher fatty amines may be straigh chained or branched, primary, secondary or tertiary, saturated or unsaturated aliphatic mono-, di- or poly-amines, and include amines prepared from naturally occurring fats and oils such as distilled cocoa amine, and distilled tallow amine.  The fatty amine salts may be derived from acetic, fumaric, lactic, adipic, malic, aspartic, carbonic, malic, glycolic, glutaric, itaconic, tartaric or succinic acid.
Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) is a disease spectrum encompassing liver injury with progressive severity, tightly connected to the metabolic syndrome. Management of MASLD mostly relies on lifestyle change aiming at improving metabolic homeostasis and insulin resistance. A Mediterranean-like dietary pattern and individualized lifestyle interventions are the cornerstone of MASLD treatment. A careful evaluation of alcohol intake and active treatment of all metabolic co-morbidities are recommended. In the MASLD spectrum, the population with liver inflammation and enhanced fibrogenesis (MASH - Metabolic-dysfunction associated steatohepatitis) can progress to advanced liver disease and has been addressed as "at-risk MASH", eligible to pharmacological treatment according to FDA and EMA. Currently there is a robust therapeutic pipeline across a variety of new targets to resolve MASH or reverse fibrosis, or both. Some of these therapies have beneficial effects that extend beyond the liver, such as effects on glycaemic control, lipid profile and weight loss. For "at-risk" MASH, reversal of fibrosis by one stage or resolution of MASH with no worsening in fibrosis as a surrogate end-point will need to be accompanied by overall survival benefits. In this review, we summarize the current evidence on lifestyle interventions in MASLD as well as pharmacological approaches for fibrosing MASH that have progressed to phase II and phase III clinical trials.
This study aimed to analyze the diagnostic performance of serum CA-125 in acute appendicitis (AA). This review was registered in PROSPERO (CRD42023450988). We included prospective and retrospective original clinical studies evaluating the diagnostic performance of serum CA-125 in AA. A search was conducted in PubMed, Web of Science, Scopus, and OVID. Search terms and keywords were: (appendicitis OR appendectomy) AND (CA-125 OR CA125). Two independent reviewers selected the articles and extracted relevant data. Methodological quality was assessed using the QUADAS-2 index. A synthesis of the results, standardization of the metrics, and three random-effect meta-analyses were performed. Five studies with data from 533 participants (including 219 patients with a confirmed diagnosis of AA and 107 controls) were included in this review. The random-effect meta-analysis of serum CA-125 (AA vs controls) included 3 articles (125 AA and 70 controls) and resulted in a non-significant mean difference [95% CI] of - 6.80 [- 20.51, 6.92] U/mL (p = 0.33). The meta-analysis by subgroups that included only male patients resulted in a significant mean difference [95% CI] of 3.48 [0.46, 6.49] U/mL (p = 0.02). Although serum CA-125 does not appear to be a good overall marker for the diagnosis of AA, our subgroup analyses show that this marker could be useful for diagnosing AA in males. It also appears to be a potentially useful tool for discriminating complicated and uncomplicated AA. However, the limited number of included studies precludes drawing generalizable conclusions. Future prospective studies focused on males and in its potential ability to discriminate between complicated and uncomplicated AA are required.Registration. PROSPERO (CRD42023450988).
Participants will be advised to consume, a low-carbohydrate diet (26-32% of calories), high in vegetable protein (28-32%) and fat (41-45%) with canola as the major component (10%). Carbohydrate sources will feature viscous fiber-containing foods (including psyllium cereal, oats and barley) and low-starch vegetables (emphasizing okra and eggplant) for the relatively limited amount of carbohydrate.